Evolutionary Tree Capital Management LLC Has $812,000 Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Evolutionary Tree Capital Management LLC reduced its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 36,262 shares of the company’s stock after selling 508 shares during the quarter. Evolutionary Tree Capital Management LLC’s holdings in Intellia Therapeutics were worth $812,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after buying an additional 746,263 shares in the last quarter. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 5.5% during the second quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company’s stock worth $259,514,000 after acquiring an additional 606,507 shares in the last quarter. Norges Bank acquired a new stake in Intellia Therapeutics during the fourth quarter valued at $16,348,000. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Intellia Therapeutics in the fourth quarter valued at about $9,086,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent research reports. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. JPMorgan Chase & Co. dropped their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.77.

Intellia Therapeutics Price Performance

NTLA stock opened at $21.88 on Friday. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -4.08 and a beta of 1.77. The company has a 50-day moving average of $23.26 and a two-hundred day moving average of $24.12. Intellia Therapeutics, Inc. has a 52-week low of $19.21 and a 52-week high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. The firm’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period last year, the firm posted ($1.40) EPS. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.